Letters Of Intent Signed For Barr To Acquire Rights To Galen’s Loestrin(r) Oral Contraceptive Product

Barr Laboratories, Inc. and have announced that they have signed a letter of intent for Barr to acquire the exclusive rights in the United States and Canada for Loestrin(R) and Loestrin(R) FE oral contraceptive products.

The proposed transaction also would include a settlement of pending litigation between Barr and Galen regarding Galen’s femhrt(R) hormone therapy and Estrostep (R) oral contraceptive products that would allow Barr to launch generic versions of those products six months prior to patent expiry.

“These agreements would add a significant new product to Barr’s growing portfolio of oral contraceptive products,” said Bruce L. Downey, Barr’s Chairman and Chief Executive Officer. “It also would allow both parties to resolve pending patent litigation in a way that will ensure Barr can bring alternative femhrt(R) and Estrostep(R) products to market prior to patent expiration, which will benefit our female healthcare products consumers.”

Commenting on the announcement, Roger Boissonneault, Galen’s Chief Executive Officer said, “This is a good deal for both companies. We would exchange a non-core asset for significant value and for a fair resolution of outstanding patent issues. While we remain confident in the strength of the Estrostep(R) and femhrt(R) patents, this transaction would allow us to remove the uncertainties inherent in any litigation. In addition, the acquisition of a generic Ovcon(R), along with introduction of our Ovcon┬« line extension, will enable us to continue to grow this important asset.”

Under the terms of a separate letter of intent, Barr would grant Galen an option to acquire an exclusive license for Barr’s generic version of Galen’s Ovcon(R) 35 oral contraceptive.

Barr has a pending Abbreviated New Drug Application (ANDA) for the 0.4 mg norethindrone/35 mg ethinyl estradiol 21-day and 28-day generic Ovcon(R) products.These transactions are subject to negotiation of definitive agreements, completion of due diligence and other conditions, including Hart-Scott-Rodino antitrust review and final approval by the Boards of Directors of both Barr and Galen.

Barr and Galen expect to close the transaction by December 31, 2003.Under the terms of the letter of intent, Barr would acquire from Galen the exclusive rights to manufacture and market Loestrin (R) products in the United States and Canada.

Galen would grant Barr a non-exclusive license to launch a generic version of femhrt(R), six months prior to the expiration of the patent on femhrt(R). Galen would also grant Barr a non-exclusive license to launch a generic version of Estrostep(R), six months prior to the expiration of the patent on Estrostep(R). Finally, Barr would receive an exclusive royalty bearing license to develop certain oral contraceptives under a patent owned by Galen.

In consideration of these rights and assets, Barr would make a one-time payment to Galen of approximately $45 million.Under the terms of the exclusive option agreement, Barr would grant Galen an option to acquire an exclusive license under Barr’s ANDA for Ovcon(R) 35, which is currently pending at the U.S. Food & Drug Administration (FDA). Within 30 days of FDA approval of Barr’s ANDA for Ovcon(R), Galen would have the right to exercise its option.

If Galen chooses to exercise the option, it would be granted a five year exclusive license under Barr’s ANDA to sell the product.

At the end of the five-year term, Barr would grant Galen a non exclusive license to continue selling the product.

In consideration of this transaction, Galen would make a $1 million payment to Barr at the time of the grant of the option and a $19 million payment to Barr at the time the exclusive license agreement is signed.

Get Steroids

dragon-pharmaceutical
Generic drug giant Dragon Pharma is offering: https://www.1steroids.net/injectable-steroids-1162/masteron-200-21853.html.

Shop Dragon Pharma LLC On-line

Sustanon 350 - Discount Price

Administration: Injection
Main Constituent: Testosterone Blend
Branded by: Dragon Pharmaceuticals
Pack: 30 x 10 mL vial (350 mg/mL)
Price: 30 x $32.00

Cut Mix 150 - Bulk Price

Administration: Injection
Active Constituent: Testosterone Propionate, Drostanolone Propionate, Trenbolone Acetate
Produced by: Dragon Pharmaceuticals
Amount: 10 x 10 mL vial (150 mg/mL)
Price: 10 x $52.00

Enantat 250 - Bulk Price

Administration: Injection
Principal Chemical Name: Testosterone Enanthate
Producer: Dragon Pharma LLC
Unit: 10 x 10 mL vial (250 mg/mL)
Price: 10 x $36.00

Clenbuterol - Bulk Price

Administration: Oral
Active Ingredient: Clenbuterol Hydrochloride
Produced by: Dragon Pharma
Amount: 10 x 100 pills (40 mcg/pill)
Price: 10 x $25.00

Enantat 250 - Discount Price

Administration: Injection
Principal Constituent: Testosterone Enanthate
Manufacturer: Dragon Pharma Labs
Amount: 30 x 10 mL vial (250 mg/mL)
Price: 30 x $25.00

Enantat 400

Injectable Anabolic Steroid
Main Ingredient: Testosterone Enanthate
Producer: Dragon Pharma Labs
Package: 1 X 10 ml (400 mg/ml)

Parabolan 100 - Cheap Price

Administration: Injection
Basic Constituent: Trenbolone Hexahydrobenzylcarbonate
Made by: Dragon Pharmaceutical
Unit: 20 x 10 mL vial (100 mg/mL)
Price: 20 x $55.00

Trenbolone 50

Injectable Anabolic Steroid
Principal Substance: Trenbolone Suspension
Branded by: Dragon Pharma LLC
Unit: 1 X 10 mL vial (50 mg/mL)

Suspension 100

Injectable Steroid for Muscle Growth
Basal Ingredient: Testosterone Suspension
Produced by: Dragon Pharma
10 mL Sterile Multi-dose Vial (100 mg/mL)

Oxymetholon

Oral Steroid for Muscle Growth
Basal Substance: Oxymetholone
Produced by: Dragon Pharmaceutical
100 tablets (50 mg/tab)

Nolvadex

Base Chemical Name: Tamoxifen Citrate
Producer: Dragon Pharma LLC
Pack: 100 tablets (50 mg/pastille)

Cypionat 250 [10 Vials]

Injectable Steroid for Muscle Growth
Active Constituent: Testosterone Cypionate
Branded by: Dragon Pharma
10 Vials [10 mL per Vial (250 mg/ml)]
Price: 10 x $36.00 = $360.00 in Total